Answers are grounded in this paper and cite their sources.
Extranodal natural killer (NK)/T-cell lymphoma is an aggressive lymphoid tumor. Optimal treatment strategies have not yet been fully defined. To explore a more effective treatment, we conducted sequential chemoradiotherapy (SCRT) and evaluated the safety and efficacy. Seventy-eight patients (51 males, 27 females) were analyzed. The complete response (CR) rate was higher for patients in the SCRT group (90.9%) than in the radiotherapy group (77.8%; p = 0.124). The relapse rate (RR) and death rate (DR) were lower in the SCRT group (RR: 6.7% vs 33.3%, p < 0.001; DR: 15.2% vs. 55.6%, p < 0.001). Progression-free survival (PFS) and overall survival (OS) rates of 5 years after diagnosis were significantly higher for patients in the SCRT group (PFS: 89%; OS: 82%) than in the radiotherapy group (PFS: 49%, p < 0.001; OS: 49%, p < 0.001). Treatment-related adverse events were more common in the SCRT group. However, the adverse events were controlled.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: